American Capital Advisory’s Acadia Pharmaceuticals ACAD Stock Holding History

American Capital Advisory’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$329	Buy	+13	New	+$286	﹤0.01%	1023

Other funds holding ACAD

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

New York State Common Retirement Fund

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

WesBanco Bank Wheeling, West Virginia $4.02B AUM 32.62% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

Handelsbanken Fonder

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return

Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

American Capital Advisory's ACAD Position: Q2 2026 in Review

American Capital Advisory opened a new position in Acadia Pharmaceuticals (ACAD) in Q2 2026: 13 shares worth $329. The stake represents ﹤0.01% of the portfolio and ranks #1023 among its holdings.

73 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

American Capital Advisory held 13 shares of Acadia Pharmaceuticals worth $329 as of Q2 2026.
Acadia Pharmaceuticals was a new American Capital Advisory position in Q2 2026.
Acadia Pharmaceuticals made up ﹤0.01% of American Capital Advisory's portfolio in Q2 2026, its #1023 holding.
73 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on American Capital Advisory's 13F filing for Q2 2026, filed 28 Jul 2026.